Overseas economic situation is grim, so many investors interested in the Chinese market. Yesterday, reporters learned from the Zhangjiang Yaogu, Hutchison Whampoa Medicine (Shanghai) Co., Ltd. and the international pharmaceutical giant Eli Lilly and Company have signed an agreement to jointly develop a new cancer target for new drugs. The partnership is the two sides in August last year to develop cancer and inflammatory diseases, since the number of targets in drug discovery once again on the "hand in hand." There are three cooperation projects, both new cancer drug target for the project, each project was put into operation several thousand yuan. Specific host and yellow pharmaceutical chemistry, biology, toxicology, metabolism and other preliminary drug research and development, all research and development carried out in China. Patent Cooperation generated during the joint application by both parties, results of medical scientists, inventors, and yellow. And yellow medicine revealed that the project is expected to be completed in the next phase of work in December. Under the agreement, Lilly will pay Hutchison medicine higher than the previous contract, signed gold deposit potential drug candidates and mileage payments, the total amount of co-operation more than 1 billion U.S. dollars. In addition, Hutchison will receive the products to the global pharmaceutical sales commission. Industry sources, and Huang Medicine and Eli Lilly created the risk-sharing, revenue sharing partnership model, on the other local Chinese bio-pharmaceutical company has an important reference, the model will improve the speed and capacity of China's drug research and development, the expansion of China in new drug R & D status and role. Research the world of cancer drugs in 53% of drug targets for the molecular biology of tumor cells characteristics, selectivity, therapeutic effect, drug side effects.

Previous: Scientists expose law Chikungunya virus mechanism will help develop new drugs
Next:no article